Introduction: Esophageal variceal bleeding is a severe complication of portal hypertension with significant morbidity and mortality. Although traditional screening and grading of esophageal varices has been performed by endogastroduodenoscopy (EGD), wireless video capsule endoscopy provides a minimally invasive alternative that may improve screening and surveillance compliance.
Aim of the Study:
The aim of the study was to perform a systematic review and structured meta-analysis of all eligible studies to evaluate the efficacy of wireless capsule endoscopy for screening and diagnosis of esophageal varices among patients with portal hypertension.
Methods: Searches of PubMed, EMBASE, Web of Science, and the Cochrane Library databases were performed through December 2015. Bivariate and hierarchical models were used to compute the pooled sensitivity and specificity, and to plot the summary receiver operating characteristics curve with summary point and corresponding 95% confidence region. Bias of included studies was assessed using the quality assessment of diagnostic accuracy studies-2.
Results: Seventeen studies from 2005 to 2015 were included in this meta-analysis (n = 1328). The diagnostic accuracy of wireless capsule endoscopy in the diagnosis of esophageal varices was 90% [95% confidence interval (CI), 0.88-0.93]. The diagnostic pooled sensitivity and specificity were 83% (95% CI, 0.76-0.89) and 85% (95% CI, 0.75-0.91), respectively. The diagnostic accuracy of wireless capsule endoscopy for the grading of medium to large varices was 92% (95% CI, 0.90-0.94). The pooled sensitivity and specificity were 72% (95% CI, 0.54-0.85) and 91% (95% CI, 0.86-0.94), respectively, for the grading of medium to large varices. The use of capsule demonstrated only mild adverse events.
A sensitivity analysis limited to only high quality studies revealed similar results.
Discussion: Wireless esophageal capsule endoscopy is well tolerated and safe in patients with liver cirrhosis and suspicion of portal hypertension. The sensitivity of capsule endoscopy is not currently sufficient to replace EGD as a first exploration in these patients, but given its high accuracy, it may have a role in cases of refusal or contraindication to EGD.
Key Words: esophageal varices, capsule, cirrhosis, portal hypertension, endogastroduodenoscopy (J Clin Gastroenterol 2017;51:174-182) E sophageal varices are common sequelae of both compensated and decompensated liver disease secondary to increased portal pressures. At the time of cirrhosis diagnosis, varices may be present in 30% to 40% of compensated cirrhotic patients and in as many as 60% of individuals with ascites and decompensated disease. [1] [2] [3] In those patients in whom varices are not present at the time of diagnosis, the annual incidence of new varices is 5% to 10%. [4] [5] [6] [7] [8] The risk of a bleed is a major concern in patients with varices. Esophageal variceal bleeding is a severe complication of portal hypertension with significant morbidity and mortality. Furthermore, the annual incidence of a first episode of bleeding among patients with varices is 12%, with each bleeding episode carrying an estimated 15% to 20% risk of mortality. 2, [9] [10] [11] [12] Therefore, the ability to appropriately screen at risk patients with a history of elevated portal pressures and liver disease is paramount to improving outcomes in liver disease patients.
To avoid the significant morbidity and mortality associated with variceal bleeding, screening, traditionally with an endogastroduodenoscopy (EGD), has been performed. If varices are present, primary prophylaxis with nonselective b-blockers (ie, propanolol or nadolol) or endoscopic band ligation has been shown to reduce the risk of first variceal hemorrhage and bleeding-related mortality. 2 Although the role of nonselective b-blockers in preventing varices in patients with cirrhosis and portal hypertension has been called in to question recently, use of this medication still dominates clinical practice. 7 Although guidelines for the American Association for the Study of Liver Diseases (AASLD) currently recommend EGD at the time of diagnosis of cirrhosis and subsequent EGD every 2 to 3 years for compensated and annually for decompensated liver disease, compliance and timely screening remain a challenge in the United States and in Europe. 2, 13 Wireless video capsule endoscopy, originally designed for evaluation of small-bowel pathology and occult bleeding, provides an alternative means for screening for esophageal varices. 14 This minimally invasive esophageal capsule endoscopy has been approved by the United States Food and Drug Administration for the detection of esophageal varices. Although capsule endoscopy has been studied and not recommended to be a viable replacement for EGD given the lack of a therapeutic basis, the minimally invasive approach, potential for widespread screening, and diagnostic capability warrant further exploration among a cirrhotic population at risk for significant variceal hemorrhage-associated morbidity and mortality. 15 The primary aim of this study was to perform a systematic review and structured meta-analysis of all eligible studies to evaluate the efficacy of wireless capsule endoscopy for screening and diagnosis of esophageal varices among patients with portal hypertension.
METHODS

Literature Search
A comprehensive search of the literature was performed to identify articles that examined the utility of wireless esophageal capsule for the screening and grading of esophageal varices. Systematic searches of PubMed, EMBASE, Web of Science, and the Cochrane Library databases were performed through December 2015 using the following search terms "wireless capsule endoscopy," "esophagus and capsule," "capsule and varices," and "capsule and variceal bleeding." All relevant articles irrespective of language, year of publication, type of publication, or publication status were included. The titles and abstracts of all potentially relevant studies were screened for eligibility. The reference lists of studies of interest were then manually reviewed for additional articles by crosschecking bibliographies. Two reviewers (T.R.M. and B.N.) independently screened the titles and abstracts of all the articles according to predefined inclusion and exclusion criteria. Any differences were resolved by mutual agreement and in consultation with the third reviewer (Y.A.). In the case of studies with incomplete information, contact was attempted with the principal authors to obtain additional data.
Study Selection Criteria
Only studies investigating the use of wireless esophageal capsule for the screening or surveillance of esophageal varices were included. Studies involving alternative endoscopic or interventional radiologic modalities were not included. Only human subject studies were considered in the analysis. A particular study was excluded if deemed to have insufficient data, as were the review articles, editorials, and correspondence letters that did not report their own data. Case series and reported studies with fewer than 5 patients were excluded. Participants included patients of any age in whom the presence of esophageal varices was suspected based on the chronic liver disease or portal vein thrombosis, irrespective of the etiology or duration of illness.
Patients with cirrhosis of Child-Pugh class A, B, or C were included as well as patients with portal vein thrombosis. Some studies included patients with varices of any size; however, some focused on detection of varices of medium or large size specifically. Studies that included patients with known varices were not excluded from the analysis. Patients who were found to have undergone a transjugular intrahepatic portosystemic shunt procedure, previous endoscopic band ligation, or endoscopic sclerotherapy of esophageal varices were excluded. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement outline for reporting systematic reviews and meta-analyses were used to report findings. 16 
Outcome Measures
The primary outcome measurements in this study were the diagnostic accuracy, sensitivity, and specificity of wireless capsule endoscopy in identifying esophageal varices in patients with portal hypertension. Secondary outcomes were the assessment of capsule endoscopy in establishing the presence of medium or large esophageal varices and the rates of complications related to capsule endoscopy.
Statistical Analysis
Included studies were analyzed according to the Cochrane DTA Working Group methodology. Measured outcomes included sensitivity and specificity of capsule endoscopy. Data were analyzed using the Stata 13.0 software package (Stata Corp LP, College Station, TX). Bivariate and hierarchical models were used to compute the pooled sensitivity and specificity and to plot the summary receiver operating characteristics curve with summary point and corresponding 95% confidence region. Briefly, this method fits a 2-level model, with binomial distributions for the combined true positive and the true negative conditional on study-specific sensitivity and specificity, and a bivariate normal model for the logit transformations for sensitivity and specificity between studies. Positive likelihood ratio (LR) and negative LR were also determined. A Fagan plot was also used to determine the meaningfulness or clinical utility. The Fagan nomogram is a graphical tool for estimating how much the result on a diagnostic test changes the probability that a patient has a disease. 17 
Index Test
The index test was the use of wireless esophageal capsule endoscopy with studies reporting evidence of esophageal varices in our analysis.
Assessment of Methodological Quality
Quality assessment of diagnostic accuracy studies (QUADAS-2) was used to assess quality in this study. QUADAS-2 is an evidence-based tool for assessment of quality in systematic reviews of diagnostic accuracy studies that is structured so that 4 key domains are rated for risk of bias and concerns regarding applicability to the research question were used to evaluate the studies. Each key domain has a set of signaling questions to assess bias and applicability. 18, 19 Disagreement among raters was resolved by consensus with the other authors. We used tabular and graphical displays in Review Manager 5 (RevMan 5.3) to summarize the QUADAS-2 assessments.
A PRISMA flow chart of search results is shown in Figure 1 . Table 1 provides baseline characteristics of included studies including etiology of liver disease, Model for End-stage Liver Disease or Child-Pugh score, and tolerability or complications if specifically stated. Both male and female patients were included. Twelve of the studies included only patients with parenchymal liver disease as a cause of portal hypertension. However, in studies that included noncirrhotic causes of portal hypertension and revealed the etiologies of portal hypertension, patients with parenchymal liver disease constituted the majority. For instance, in 1 study, <23% of patients actually had noncirrhotic cause of their portal hypertension. 22 The majority of patients in the studies had alcohol, viral, or nonalcoholic steatohepatitis-induced liver disease; however, patients with primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis were also included. Studies included in this meta-analysis had variable numbers of patients with compensated versus decompensated cirrhosis although the overall majority of patients in the studies had compensated cirrhosis.
The capsule device used in these studies was the firstgeneration or second-generation Pillcam capsule. In 16 studies, the accuracy of capsule endoscopy in assessing the presence of any varices regardless of size was estimated. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] The remaining 1 study assessed the accuracy of capsule endoscopy for only large, high-risk esophageal varices. 36 A total of 7 studies evaluated the use of wireless capsule endoscopy for medium or large varices. 22, 27, 28, [32] [33] [34] 36 A forest plot is shown in Figure 2 . The accuracy of each individual study assessing the diagnosis and grading of esophageal varices is illustrated in Figure 3 .
Quality Assessment of Included Studies
The quality of the eligible studies was assessed by QUADAS-2 criteria and is reported in Figure 4 . In most studies, there was a low risk of bias regarding the selection of patients; however, 8 studies in total demonstrated a high risk of bias. There was no risk of bias issues of the index test in any of the studies. In most studies, there was a low risk of bias to determine whether an appropriate reference standard was used or its applicability.
Capsule Endoscopy for Screening
The pooled estimates of sensitivity and specificity of wireless capsule endoscopy in the diagnosis of esophageal varices were calculated as above. The diagnostic accuracy of capsule endoscopy was 90% [95% confidence interval (CI), 0.88-0.93; Fig. 5 ]. A total of 16 studies assessing varices of any size demonstrated pooled of sensitivity and specificity of 83% (95% CI, 0.76-0.89) and 85% (95% CI, 75-0.91), respectively. The pooled positive LR and negative LR were 5.4 (95% CI, 3.3-9.0) and 0.20 (95% CI, 0.14-0.28), respectively. The diagnostic odds ratio was 27 (95% CI, 14-54). When the 8 studies with high risk of bias were excluded, the pooled sensitivity and specificity of capsule endoscopy for screening of esophageal varices were similar [sensitivity of 80% (95% CI, 0.73-0.85) and specificity of 86% (95% CI, 0.68-0.94), Supplemental presence of varices, the posttest probability that the patient truly has varices would be approximately 60%. Alternatively, if the patient tests negative (ie, no varices are seen on capsule endoscopy), the posttest probability that the patient truly has varices would be <5%. Again, when studies with a high risk of bias were excluded from analysis, the Fagan nomogram demonstrated similar results (Supplemental Fig. 3 , Supplemental Digital Content 3, http://links.lww.com/JCG/A268).
Capsule Endoscopy for Grading
Subgroup analysis was performed for studies specifically evaluating the grading of medium and large varices. The diagnostic accuracy of wireless capsule endoscopy for medium to large varices was 92% (95% CI, 0.90-0.94; Fig. 7 ). Of the 7 included studies, the pooled sensitivity was 72% (95% CI, 0.54-0.85). The pool specificity in grading medium to large varices was 91% (95% CI, 0.86-0.94). The positive LR, negative LR, and odds ratio were 8.1 (95% CI, 4.8-13. A Fagan plot with regard to grading of esophageal varices demonstrated that with a low pretest probability (20%) of medium to large varices, if capsule revealed medium to large varices, the posttest probability that the patient truly has varices would be approximately 70%. In the face of a negative test, the posttest probability that the patient actually has medium to large varices would be <7% (Fig. 8) . The Fagan nomogram was also analyzed after studies with a high risk of bias were excluded and resulted in a similar clinical utility (Supplemental Fig. 6 , Supplemental Digital Content 6, http://links.lww.com/JCG/A271).
Adverse Events
Although participants reported minor discomfort due to the process of swallowing the capsule in the majority of studies, only 2 significant adverse events were reported. These included 2 episodes of nausea or vomiting secondary to capsule retention as caused by an unsuspected esophageal stricture. Of these 2 significant adverse events, only 1 required EGD for the recovery of capsule. 22, 26, 29, 31, 32, 36 
DISCUSSION
The results of this study confirm the feasibility, safety, and tolerance of wireless capsule endoscopy in the diagnosis and grading of esophageal varices among patients with liver cirrhosis and suspicion of portal hypertension. This study also demonstrated that the sensitivity of capsule endoscopy is not currently sufficient to replace EGD as a first exploration in these patients, but given its high accuracy, it may have a role in cases of refusal or contraindication to EGD.
The need for appropriate screening and surveillance stems from the significant morbidity and mortality of variceal hemorrhage. Variceal bleeding accounts for 70% of all upper gastrointestinal bleeding episodes in patients with liver cirrhosis. 37 Although variceal size is the most useful predictor for incidence of variceal bleeding, other important factors for the development of variceal bleeding include severity of liver dysfunction (ie, Child-Pugh classification and Model for End-stage Liver Disease score) and red wale signs. 3 The ability to accurately grade varices is paramount as it changes surveillance recommendations. 2 Although the sensitivity of capsule endoscopy is not sufficient to replace EGD, capsule demonstrated a diagnostic accuracy of 92% in assessing medium to large grade varices-those that require treatment with b-blockers or band ligation.
At this time, the PillCam ESO2 capsule is the only wireless capsule endoscopic modality currently available for esophageal application. 38 Although similar in design to the second-generation Pillcam SB2 (designed for small-bowel observation), the battery life is significantly shorter (20 min vs. 8 to 12 h, respectively). The minimally invasive nature of the modality provides a particularly important aspect of expanding its use, provided the patient is able to swallow the capsule -the most frequent adverse event reported in this cohort of studies. Further barriers to clinical application and expanded use in practice include capsule interpretation. At present, the American Society For Gastrointestinal Endoscopy recommends formal capsule training during fellowship or completion of a formal society-endorsed training course with proctoring of the first 10 capsule interpretations. 39 Although required formal training presents a barrier to expansion of this modality, the increased use of capsule endoscopy in the evaluation of both esophageal and smallbowel pathology necessitates that gastroenterologists become more adept at interpretation.
Further discussion regarding capsule interpretation requires an understanding of positive and negative results. The Fagan nomogram for capsule demonstrated the clinical utility of this modality. Even in patients with a modest to low pretest probability, wireless capsule endoscopy is an effective modality for ruling out the presence of varices as well as grading medium to large varices. When studies with a high risk of bias were excluded, a similar clinical utility was demonstrated. It is important to consider, additional factors that may influence the use of EGD over capsule or vice versa, including the cost of the modality, availability, as well as the likelihood for therapeutic intervention. Further cost-effectiveness analysis should be performed to best estimate the true utility of capsule in the diagnosis and grading of esophageal varices in patients with liver disease.
Aside from the small, inherent heterogeneity limitations of meta-analyses that exist between studies, a major limitation of this study is the modality of choice. Only 1 study, by Sacher-Huvelin et al, 32 used the second-generation Pillcam. All other studies included used the firstgeneration modality. In this French study, the sensitivity of capsule endoscopy in correctly diagnosing and staging esophageal varices was 76% and 64%, respectively; the specificity of the test was 91% and 93%, demonstrating that although capsule endoscopy is not sufficient at this time for the initial diagnosis of esophageal varices, the high specificity of the test may allow its use in cases where patients are refusing or are unable to undergo EGD. 32 The accuracy of capsule for diagnosis and grading was 84% and 81%, respectively. This lower value may indicate the pooled accuracy of this study may be overestimated; thereby requiring more studies with the newer generation before a change in guidelines or surveillance recommendations are made. In addition, of the included studies, there was a high risk of bias (8 of the total 17 studies) that may limit generalizability of these results; however, separate analysis excluded these studies was performed and yielded similar results. Overall, based upon the current quality of evidence, more studies are needed to further evaluate the role of wireless capsule endoscopy for patients with portal hypertension.
Despite these limitations, this systematic review and meta-analysis has several strengths. Apart from summarizing all methodologically rigorous data on wireless capsule endoscopy for the diagnosis and grading of esophageal varices in patients with portal hypertension, this study allowed for determination of a pooled sensitivity, specificity, and accuracy to support the use of capsule as an accurate modality in patients with decreased access to endoscopic screening or contraindication to EGD. Although our reported results are similar to a previous Cochrane Database Systematic Review by Colli et al, 15 the addition of more recent studies, implementation of the Fagan nomogram, and assessment of clinical utility are paramount to reporting the best evidence on the effectiveness of capsule endoscopy. Furthermore, this pooled data coupled with an understanding of clinical utility, may provide a pivotal tool to guide primary care physicians, practicing gastroenterologists, and hepatologists caring for these patients with portal hypertension. At present, there is a paradigm shift in the field of gastroenterology and hepatology with regard to the diagnosis and screening of liver disease (ie, less invasive testing for liver fibrosis and less reliance on traditional liver biopsy). With this changing landscape to identify liver disease and degree of fibrosis, the assessment of liver-associated sequelae such as esophageal varices from a less invasive means will become pivotal. 40 In summary, given the significant morbidity and mortality associated with variceal hemorrhage, alternative screening and diagnostic measures are needed to expand beyond the use of simple endoscopy. Although EGD remains the gold standard, and should continue to be standard of care for the diagnosis and management of patients with known varices, this study demonstrated that wireless capsule endoscopy is an effective alternative modality for the diagnosis and grading of esophageal varices and may have a role in cases of refusal or contraindication to EGD. The role for wireless esophageal capsule endoscopy remains limited as this modality lacks any potential therapeutic intervention. Furthermore, based upon the current quality of overall evidence, more studies are needed to evaluate the use of wireless capsule endoscopy for screening and grading of esophageal varices. Nonetheless, this minimally invasive approach may improve overall compliance with AASLD screening and surveillance recommendations and thus expand the indication to provide prophylactic pharmacologic therapy to patients with portal hypertension.
